SGIOF — SHIONOGI & CO LTD
—
OTC ·
Unknown ·
Unknown ·
CIK 1281721 ·
Last close
$17.68
Market Cap
$15.05B
52W High
$23.39
52W Low
$17.68
ADV30
1,357
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2025 | — | — | — | — | — | — | — |
| Mar 2025 | — | — | — | — | 1,535,349,000,000 | 374,795,000,000 | 172,853,000,000 |
| Sep 2024 | — | — | — | — | 1,456,729,000,000 | 303,405,000,000 | 145,930,000,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$1,115,729,000,000
Inventory
$65,477,000,000
Receivables
—
ST Investments
$270,024,000,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$499,677,003,776
EBITDA
$151,324,000,256
Free Cash Flow
$-11,198,624,768
Enterprise Value
$-10,968,754,176
Total Cash
$711,397,015,552
Total Debt
$684,394,020,864
Shares Out
850,975,437
Trailing EPS
$1.26
Book Value
$11.20
ROE
13.5%
ROA
3.8%
Div Yield
2.74%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 438,268,000,000 | 156,604,000,000 | 170,435,000,000 | 1,535,349,000,000 | 172,853,000,000 | — | 195,460,000,000 |
| Mar 2024 | 435,081,000,000 | 153,312,000,000 | 162,030,000,000 | 1,416,918,000,000 | 164,357,000,000 | — | 154,284,000,000 |
| Mar 2023 | 426,684,000,000 | 149,004,000,000 | 184,965,000,000 | 1,311,800,000,000 | 189,922,000,000 | — | 177,867,000,000 |
| Mar 2022 | 335,138,000,000 | 110,312,000,000 | 114,185,000,000 | 1,150,601,000,000 | 157,316,000,000 | — | 102,068,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.24
News headlines (Yahoo Finance, 1h cache)
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
2026-05-13 21:08 · Yahoo
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
D-Wave CEO on quantum computing's ChatGPT moment, Nvidia, & more
2026-04-14 15:23 · Yahoo
Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook
2026-04-13 00:21 · Yahoo
The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
2026-04-10 12:00 · Yahoo
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
2026-04-10 11:10 · Yahoo
Shionogi secures $482m BARDA contract to tackle AMR crisis
2026-04-09 10:06 · Yahoo
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
2026-04-08 12:30 · Yahoo
ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections
2026-04-07 12:30 · Yahoo
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
2026-04-01 23:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.